Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial
Abstract Clostridioides difficile infection (CDI) is a significant cause of hospital-acquired diarrhea, leading to high morbidity, recurrence, and healthcare costs. Probiotics like Saccharomyces boulardii show potential as an adjunct therapy to standard CDI treatment, but further trials are needed t...
Saved in:
| Main Authors: | Taned Chitapanarux, Umaporn Wiracha, Poramed Winichakoon, Parichat Salee, Patrinee Traisathit |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-04986-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection
by: Jasna Rahimić, et al.
Published: (2025-04-01) -
Metronidazole and Vancomycin Have a Synergic Effect, with Plant Extracts as Helpful Tools to Combat <i>Clostridioides difficile</i> Infections
by: Nancy C. Ruiz-Pérez, et al.
Published: (2025-01-01) -
Risk factors for further recurrences of Clostridioides difficile infection at the first and second recurrence: a retrospective cohort
by: Måns Stefansson, et al.
Published: (2025-08-01) -
Evaluation of three commercial rapid immunoassays for the diagnosis of Clostridioides difficile infection
by: Hannes Bjarki Vigfússon, et al.
Published: (2025-08-01) -
Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection
by: Shaodong Wei, et al.
Published: (2022-12-01)